Skip to main content
You are the owner of this article.
You have permission to edit this article.
Edit
Experimental Covid antibody treatment that Trump lauded now available in WNY

Experimental Covid antibody treatment that Trump lauded now available in WNY

Support this work for $1 a month
Covid-19 treatments

Dr. Sanjay Sethi, director of the University at Buffalo Clinical Research Office, says the office is enrolling those eligible for the new coronavirus investigational monoclonal antibody cocktail REGN-COV2, manufactured by Regeneron Pharmaceuticals. 

Western New Yorkers recently exposed to a household member who tests positive with Covid-19 can be treated with a promising drug that researchers believe can help treat a coronavirus infection.

The University at Buffalo Clinical Research Office is leading the regional effort of a national Regeneron Pharmaceuticals clinical trial to help measure the effectiveness of the investigational antibody cocktail REGN-COV2.

This therapy was among the treatments President Donald Trump received in early October at Walter Reed Medical Center after contracting the novel coronavirus.

Trump credited the therapy for helping him recover.

“At a time when our region is unfortunately experiencing an uptick in cases, we are pleased that we are able to provide Western New Yorkers with the opportunity to enroll in a study of this very promising potential Covid-19 treatment,” said Dr. Sanjay Sethi, chief of the Division of Pulmonary, Critical Care and Sleep Medicine in the UB Jacobs School of Medicine and Biomedical Sciences and study principal investigator.

Sethi is also medical director of the UB Clinical Research Office and a physician with UBMD Internal Medicine.

The monoclonal antibody treatment is believed to reduce the severity of symptoms in those exposed to Covid-19, and possibly prevent them.

“If, for example, I test positive, then any member of my household could be eligible for this treatment provided that they haven’t begun experiencing symptoms,” Sethi said.

Those interested in treatment must be 18 or older, live with someone recently tested positive with the coronavirus and be free of Covid-19 symptoms, said Kelly Green, clinical research coordinator with the Clinical Research Office.

Those who do, can call Green at 888-4764 or email kjk22@buffalo.edu for more information and to see if they meet other eligibility guidelines for treatment.

Regeneron sought 2,000 patients when the study started several weeks ago in the region. There are 700 slots still available and more may be added depending on interest, Green said.

The drugmaker decided to provide treatment because Dr. Michael Cain, Jacobs School dean, was able to provide space in an unused medical school clinic in Amherst where participants could be treated discretely and safely without exposing other health care patients, Sethi said.

Those selected for the study will get a rapid test for Covid-19. They will be able to participate whether they test positive or negative. Those who are symptomatic will not be eligible but could consider participating in treatment trials being conducted at UB for mild to moderate cases of Covid-19.

Convalescent plasma, donated from people who recovered from Covid-19, is among those treatments. The Regeneron antibody drug is made in the laboratory and designed to bind to the spiked protein of the coronavirus, possibly blocking its ability to invade cells and multiply.

Participants will get a single subcutaneous (under the skin) injection of either the treatment or a placebo. Because the study is double-blind, neither the participant nor health care personnel administering the injection will know which of the two are being given.

Concerned about COVID-19?

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

  • Updated

College nursing student Alex Hubert got over a mild case of Covid-19 in March. Retired college professor Gerald Krzemien spent 33 days at Buffalo General Medical Center – including 11 in intensive care – with a much more serious case. Both landed on opposite ends of an antibody infusion, a new treatment expected to grow more common around the

  • Updated

Below you’ll find our daily coverage of the Covid-19 outbreak. We know that trusted information is important for the health and safety of our region, and our subscribers make it possible for us to provide that. 

Get up-to-the-minute news sent straight to your device.

Topics

News Alerts

Breaking News